Science
Massimiliano Cani։ Evaluating the Use of Cytisine for Smoking Cessation in Lung Cancer Screening Programs
Massimiliano Cani/LinkedIn

Massimiliano Cani։ Evaluating the Use of Cytisine for Smoking Cessation in Lung Cancer Screening Programs

Massimiliano Cani, Research Fellow at Gustave Roussy, PhD Student at Università degli Studi di Torino, shared on LinkedIn:

“Now online on JTO.

Smoking cessation is a key component of lung cancer screening programs. In this setting, cytisine represents a highly effective treatment option, as demonstrated by our study involving nearly 3,500 participants, including approximately 1,300 treated within the RISP trial.
Key findings:

  • Smoking cessation rate with cytisine: 50.1% (vs 8.1% with counseling alone)
  • Adverse events were mild and readily manageable

An important study supporting the integration of effective smoking cessation strategies into lung cancer screening programs.

Thanks to all the RISP network, all co-authors and more importantly to Dr. Pastorino and Pr. Silvia Novello.”

Title: Cytisine for Smoking Cessation Within a Lung Cancer Screening Program: Results From the Italian RISP Trial

Authors: Massimiliano Cani, Daniela Bafunno, Francesca Caumo, Silvia Novello, Salvatore Cardellicchio, Vincenzo Cilenti, Elena Davoli, Edoardo Mercadante, Ciro Battiloro, Aldo Cammarota, Sandro Sironi, Vito Barbieri, Vito Ladisa, Roberto Boffi, Beatrice Cosentino, Mariam El Hayek, Ugo Pastorino, RISP Collaborative Group

Read the article

Other articles about lung cancer on OncoDaily.

Aldo Cammarota Beatrice Cosentino Ciro Battiloro Daniela Bafunno Edoardo Mercadante Elena Davoli Francesca Caumo Lung cancer Mariam El Hayek Massimiliano Cani RISP Collaborative Group Roberto Boffi Salvatore Cardellicchio Sandro Sironi Silvia Novello Ugo Pastorino Vincenzo Cilenti Vito Barbieri Vito Ladisa